MedTrace Logo

Renal Denervation to Treat Heart Failure With Preserved Ejection Fraction

NCT05030987 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2024-07-17

No results posted yet for this study

Summary

Heart failure with preserved ejection fraction has a high mortality, which is contrasted by a total absence of therapy options besides symptomatic diuretic treatment. This study aims to explore the potential of renal denervation as a treatment option for heart failure with preserved ejection fraction.

Conditions

Interventions

PROCEDURE

Renal Denervation

Renal denervation in patients with HFpEF and uncontrolled hypertension

PROCEDURE

Sham

Sham Treatment. After six months, cross-over is planned in all sham-treated patients and this patients will also receive a renal denervation.

Sponsors & Collaborators

  • ReCor Medical, Inc.

    collaborator INDUSTRY

  • University of Leipzig

    lead OTHER

Principal Investigators

  • Karl Fengler, PhD · Herzzentrum Leipzig, Universitätsklinik für Kardiologie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-30
Primary Completion
2024-12-31
Completion
2026-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05030987 on ClinicalTrials.gov